Agios Pharmaceuticals Inc Stock Price, News & Analysis

Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 14, 2025, at 8:00 AM PT/11:00 AM ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A recording of the presentation will remain available on the company's website for a minimum of two weeks after the event.

Agios Pharmaceuticals (NASDAQ: AGIO) reported its Q1 2025 financial results and business updates. PYRUKYND generated $8.7 million in net revenue, up from $8.2 million in Q1 2024, with 136 patients currently on therapy. The FDA is reviewing PYRUKYND's sNDA for thalassemia treatment with a PDUFA date of September 7, 2025. The Phase 3 RISE UP study for sickle cell disease is progressing with topline results expected in late 2025. Financially, Agios reported a net loss of $89.3 million for Q1 2025, compared to $81.5 million in Q1 2024. The company maintains a strong cash position of $1.4 billion as of March 31, 2025. R&D expenses increased to $72.7 million, while SG&A expenses rose to $41.5 million due to commercial preparation activities.

Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has scheduled its first quarter 2025 financial results conference call and webcast for May 1, 2025, at 8:00 a.m. ET. The event will cover Q1 2025 financial performance and business updates.

The webcast will be available through the Investors section of Agios' website under Events & Presentations, with a replay accessible approximately two hours after the event.

Agios Pharmaceuticals (NASDAQ: AGIO) has announced inducement equity grants to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan. The grants, approved by the Board on March 5, 2025, include:

• A nonstatutory option to purchase 55,374 shares at $33.95 per share, vesting over four years
• 24,300 restricted stock units vesting in equal annual installments over three years
• 16,200 performance stock units tied to specific milestones

The grants were made outside the Company's 2023 Stock Incentive Plan as inducements for employment, complying with Nasdaq Listing Rule 5635(c)(4). The option price reflects AGIO's closing share price on March 5, 2025.

Agios Pharmaceuticals (Nasdaq: AGIO), a pioneer in cellular metabolism and PK activation therapies for rare diseases, has announced upcoming management presentations at two major investor conferences in March 2025.

The company will participate in:

• A fireside chat at the Leerink Global Healthcare Conference 2025 on March 11, 2025, at 10:50 a.m. ET
• A fireside chat at the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, at 12:30 p.m. ET

Both presentations will be available via live webcast on the Investors section of Agios's website under 'Events & Presentations'. Replay recordings will remain accessible for a minimum of two weeks after each presentation.

Agios Pharmaceuticals (Nasdaq: AGIO), a company specializing in cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the TD Cowen 45th Annual Healthcare Conference. The company's management team will deliver a presentation on Monday, March 3, 2025, at 10:30 a.m. ET.

The presentation will be accessible through a live webcast on the Investors section of Agios's website (www.agios.com) under the Events & Presentations tab. Interested parties who cannot attend the live presentation can access a replay of the webcast, which will remain available on the company's website for a minimum of two weeks following the event.

Agios Pharmaceuticals (AGIO) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its PYRUKYND franchise. The company generated $10.7 million in Q4 PYRUKYND net revenue, a 20% increase from Q3 2024. For the full year 2024, PYRUKYND revenue reached $36.5 million.

Key developments include regulatory filings for mitapivat (PYRUKYND) in thalassemia across four markets, with an FDA PDUFA date of September 7, 2025. The company completed enrollment for its Phase 3 RISE UP study in sickle cell disease, with topline results expected in late 2025.

Financial highlights show a Q4 net loss of $96.5 million, while the full year 2024 recorded a net income of $673.7 million. The company maintains a strong cash position of $1.5 billion as of December 31, 2024, supported by royalty monetization and milestone payments.

Agios Pharmaceuticals (AGIO) announced positive results from its Phase 3 ACTIVATE-Kids study of mitapivat in children with Pyruvate Kinase (PK) deficiency. The study met its primary endpoint of hemoglobin response in non-regularly transfused patients aged 1 to <18 years.

The trial enrolled 30 patients, with 19 receiving mitapivat and 11 receiving placebo. 31.6% (6/19) of patients in the mitapivat arm achieved hemoglobin response compared to 0% in the placebo arm. The safety profile was consistent with previous adult studies, with no treatment discontinuations due to adverse events.

This marks Agios' first pediatric clinical program for rare hemolytic anemia, following the previously reported positive results from ACTIVATE-KidsT study in regularly transfused children. Based on these results, Agios plans to submit a marketing application for mitapivat in pediatric PK deficiency patients.

Agios Pharmaceuticals (AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has announced it will host a conference call and live webcast to discuss its fourth quarter and full year 2024 financial results. The event is scheduled for Thursday, February 13, 2025, at 8:00 a.m. ET. The webcast will be available on the company's website under the Investors section, with a replay accessible approximately two hours after the event.